TERN (STOCKS)
Terns Pharmaceuticals, Inc. Common Stock
$52.520000
-0.110000 (-0.21%)
Prev close: $52.630000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Amy L. Burroughs
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $6,070.74M
- Employees
- 59
- P/E (TTM)
- -50.95
- P/B (TTM)
- 5.87
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
4
Buy
8
Hold
0
Sell
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Costs And Expenses | $110.12M |
| Nonoperating Income/Loss | $14.50M |
| Operating Income/Loss | -$110.12M |
| Income/Loss From Continuing Operations After Tax | -$96.21M |
| Income/Loss From Continuing Operations Before Tax | -$95.63M |
| Income Tax Expense/Benefit | $581.00K |
| Income Tax Expense/Benefit, Current | $231.00K |
| Income Tax Expense/Benefit, Deferred | $350.00K |
| Net Income/Loss | -$96.21M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$96.21M |
| Net Income/Loss Available To Common Stockholders, Basic | -$96.21M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.03 |
| Diluted Earnings Per Share | -$1.03 |
| Basic Average Shares | 93,166,571 |
| Diluted Average Shares | 93,166,571 |
| Assets | $1.03B |
| Current Assets | $1.02B |
| Noncurrent Assets | $884.00K |
| Fixed Assets | $47.00K |
| Other Non-current Assets | $837.00K |
| Liabilities | $18.55M |
| Current Liabilities | $16.41M |
| Accounts Payable | $1.72M |
| Wages | $6.92M |
| Other Current Liabilities | $7.77M |
| Noncurrent Liabilities | $2.14M |
| Equity | $1.01B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.01B |
| Liabilities And Equity | $1.03B |
| Net Cash Flow From Operating Activities | -$82.18M |
| Net Cash Flow From Operating Activities, Continuing | -$82.18M |
| Net Cash Flow From Investing Activities | -$298.04M |
| Net Cash Flow From Investing Activities, Continuing | -$298.04M |
| Net Cash Flow From Financing Activities | $743.51M |
| Net Cash Flow From Financing Activities, Continuing | $743.51M |
| Exchange Gains/Losses | $16.00K |
| Net Cash Flow | $363.31M |
| Net Cash Flow, Continuing | $363.29M |
| Comprehensive Income/Loss | -$95.67M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$95.67M |
| Other Comprehensive Income/Loss | $539.00K |